PMID- 30409302
OWN - NLM
STAT- MEDLINE
DCOM- 20191213
LR  - 20191217
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 86
DP  - 2018 Nov
TI  - From VA Larynx to the future of chemoselection: Defining the role of induction 
      chemotherapy in larynx cancer.
PG  - 200-205
LID - S1368-8375(18)30349-X [pii]
LID - 10.1016/j.oraloncology.2018.09.026 [doi]
AB  - Organ preservation protocols utilizing induction chemotherapy as a selection 
      agent have played a critical role in the treatment of advanced laryngeal squamous 
      cell carcinoma (LSCC). The selection of patients who will have a good response to 
      chemoradiation allows for organ preservation in a significant group of patients 
      and minimizes the rate of surgical salvage. While there remains debate regarding 
      its utility when compared to surgery or other organ preservation regimens, the 
      data does suggest an important role for induction chemotherapy in LSCC. In 
      addition, there are continued opportunities to identify pretreatment biomarkers 
      for induction chemotherapy, whether genetic, epigenetic or cellular, that could 
      predict response to treatment and select patients to therapy (whether organ 
      preservation or surgery). As our understanding of the biology of larynx cancer 
      advances, induction paradigms have utility for the development and adoption of 
      novel agents and therapeutics. The background of induction chemotherapy as a 
      selection agent and future directions of this approach are discussed.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Spector, Matthew E
AU  - Spector ME
AD  - Department of Otolaryngology - Head and Neck Surgery, United States; 
      Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, 
      MI, United States. Electronic address: mspector@umich.edu.
FAU - Rosko, Andrew J
AU  - Rosko AJ
AD  - Department of Otolaryngology - Head and Neck Surgery, United States; 
      Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, 
      MI, United States.
FAU - Swiecicki, Paul L
AU  - Swiecicki PL
AD  - Department of Otolaryngology - Head and Neck Surgery, United States; Department 
      of Internal Medicine, Division of Hematology and Oncology, United States.
FAU - Chad Brenner, J
AU  - Chad Brenner J
AD  - Department of Otolaryngology - Head and Neck Surgery, United States; 
      Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, 
      MI, United States.
FAU - Birkeland, Andrew C
AU  - Birkeland AC
AD  - Department of Otolaryngology - Head and Neck Surgery, United States; 
      Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, 
      MI, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181001
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Chemotherapy, Adjuvant/methods/trends
MH  - Clinical Trials, Phase III as Topic
MH  - Disease-Free Survival
MH  - Fluorouracil
MH  - Humans
MH  - Induction Chemotherapy/*methods/trends
MH  - Laryngeal Neoplasms/mortality/pathology/*therapy
MH  - Laryngectomy/methods/trends
MH  - Larynx/pathology/surgery
MH  - Neoplasm Staging
MH  - Organ Sparing Treatments/methods/trends
MH  - *Patient Selection
MH  - Randomized Controlled Trials as Topic
MH  - Squamous Cell Carcinoma of Head and Neck/mortality/pathology/*therapy
MH  - United States
MH  - United States Department of Veterans Affairs
OTO - NOTNLM
OT  - Advanced laryngeal squamous cell carcinoma
OT  - Chemoselection
OT  - Induction selection
OT  - Organ preservation therapy
EDAT- 2018/11/10 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/11/10 06:00
PHST- 2018/06/24 00:00 [received]
PHST- 2018/09/11 00:00 [revised]
PHST- 2018/09/18 00:00 [accepted]
PHST- 2018/11/10 06:00 [entrez]
PHST- 2018/11/10 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - S1368-8375(18)30349-X [pii]
AID - 10.1016/j.oraloncology.2018.09.026 [doi]
PST - ppublish
SO  - Oral Oncol. 2018 Nov;86:200-205. doi: 10.1016/j.oraloncology.2018.09.026. Epub 
      2018 Oct 1.